Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to explore the efficacy and the safety of polyene phosphatidylcholine Injection in patients with acute drug-induced liver injury after 2-4 weeks of treatment.


Clinical Trial Description

This study is a phase IV study in subjects with acute drug-induced liver injury. As designed, the study will include a screening period of up to 1 week, 2 to 4 weeks of treatment, and 1 week of safety follow-up. The eligible subjects will randomly be assigned to polyene phosphatidylcholine group or magnesium isoglycyrrhizinate group to receive single-blind treatment with a ratio of 1:1. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04595916
Study type Interventional
Source Haisco Pharmaceutical Group Co., Ltd.
Contact
Status Completed
Phase Phase 4
Start date April 4, 2020
Completion date November 2, 2020